相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus
A. Sidney Barritt et al.
GASTROENTEROLOGY (2012)
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: A randomized phase II study
Michael P. Manns et al.
HEPATOLOGY (2012)
Host genomics and HCV treatment response
Paul J. Clark et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)
C. Hezode et al.
JOURNAL OF HEPATOLOGY (2012)
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase ha, open-label study
Christophe Moreno et al.
JOURNAL OF HEPATOLOGY (2012)
Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow
Tarik Asselah et al.
LIVER INTERNATIONAL (2012)
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial
Michael Manns et al.
ANTIVIRAL THERAPY (2011)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
Oliver Lenz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
Alexander J. Thompson et al.
GASTROENTEROLOGY (2010)
Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients
Henk W. Reesink et al.
GASTROENTEROLOGY (2010)
Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study
Andri Rauch et al.
GASTROENTEROLOGY (2010)
In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor
Tse-I Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Vijayaprakash Suppiah et al.
NATURE GENETICS (2009)
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Yasuhito Tanaka et al.
NATURE GENETICS (2009)
SCH 503034, a novel hepatitis C virus pro-tease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: A phase Ib, placebo-controlled, randomized study
Hendrik W. Reesink et al.
GASTROENTEROLOGY (2006)
Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C
L Kleinman et al.
QUALITY OF LIFE RESEARCH (2000)
分享论文
